IL10 and rheumatoid arthritis: After that, the low-dose cytokine combination [IL-4, IL-10, and anti-IL-1 antibodies (10 fg/mL)] therapy also exhibited the promising prospect in rheumatoid arthritis, at a randomized, open, active-controlled, prospective, phase IV trial (Martin-Martin et al., 2017).